146 related articles for article (PubMed ID: 458812)
1. Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
van't Riet B; Wampler GL; Elford HL
J Med Chem; 1979 May; 22(5):589-92. PubMed ID: 458812
[TBL] [Abstract][Full Text] [Related]
2. New ribonucleotide reductase inhibitors with antineoplastic activity.
Elford HL; Wampler GL; van't Riet B
Cancer Res; 1979 Mar; 39(3):844-51. PubMed ID: 427774
[No Abstract] [Full Text] [Related]
3. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.
Szekeres T; Fritzer-Szekeres M; Elford HL
Crit Rev Clin Lab Sci; 1997; 34(6):503-28. PubMed ID: 9439883
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of benzohydroxamic acid inhibitors of ribonucleotide reductase.
van't Riet B; Kier LB; Elford HL
J Pharm Sci; 1980 Jul; 69(7):856-7. PubMed ID: 6993654
[TBL] [Abstract][Full Text] [Related]
5. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of acyclonucleoside hydroxamic acids as inhibitors of ribonucleotide reductase.
Farr RA; Bey P; Sunkara PS; Lippert BJ
J Med Chem; 1989 Aug; 32(8):1879-85. PubMed ID: 2666666
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
Szekeres T; Gharehbaghi K; Fritzer M; Woody M; Srivastava A; van't Riet B; Jayaram HN; Elford HL
Cancer Chemother Pharmacol; 1994; 34(1):63-6. PubMed ID: 8174204
[TBL] [Abstract][Full Text] [Related]
8. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Tihan T; Elford HL; Cory JG
Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
[TBL] [Abstract][Full Text] [Related]
9. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
10. Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
Cory JG; Cory AH; Raber NK; Narayanan A; Schneller SW
Adv Enzyme Regul; 1993; 33():129-40. PubMed ID: 8356905
[TBL] [Abstract][Full Text] [Related]
11. Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents.
Elford HL; Van't Riet B; Wampler GL; Lin AL; Elford RM
Adv Enzyme Regul; 1980; 19():151-68. PubMed ID: 6175187
[No Abstract] [Full Text] [Related]
12. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Matsumoto M; Fox JG; Wang PH; Koneru PB; Lien EJ; Cory JG
Biochem Pharmacol; 1990 Oct; 40(8):1779-83. PubMed ID: 2242014
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamine.
FitzGerald GB; Wick MM
Biochem Pharmacol; 1985 Feb; 34(3):353-60. PubMed ID: 3882092
[TBL] [Abstract][Full Text] [Related]
16. Effects of benzohydroxamic acids on L1210 lymphoid leukemia cell nucleic acid metabolism.
Hall IH; Taylor K; Izydore RA; Daniels DL
Pharmazie; 1998 Nov; 53(11):794-9. PubMed ID: 9853360
[No Abstract] [Full Text] [Related]
17. Antitumor effects of biologic reducing agents related to 3,4-dihydroxybenzylamine: dihydroxybenzaldehyde, dihydroxybenzaldoxime, and dihydroxybenzonitrile.
Wick MM; FitzGerald GB
J Pharm Sci; 1987 Jul; 76(7):513-5. PubMed ID: 3312571
[TBL] [Abstract][Full Text] [Related]
18. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
19. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
20. Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Cory JG; Downes DL; Cory AH; Schaper KJ; Seydel JK
Anticancer Res; 1994; 14(3A):875-9. PubMed ID: 8074487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
